Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
11β-MNTDC Safety and PK in Healthy Men
NCT03298373Phase 1Unknown
- Sponsor
- Premier Research
- Start
- Nov 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 11β-methyl nortestosterone dodecylcarbonate in male contraception, sponsored by Premier Research. Primary endpoints: Incidence of treatment emergent adverse events at 28 days, Changes from baseline in sodium, potassium, chloride, bicarbonate, calcium at 28 days and 4 more. Status: unknown.
02
Drugs
11β-methyl nortestosterone dodecylcarbonate
03
Conditions
male contraception
Beyond the preview
Go deeper on NCT03298373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298373.